Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Metabolism. 2017 Mar 9;71:70–82. doi: 10.1016/j.metabol.2017.03.005

Figure. 3. The caspase-1 inhibitor, YVAD, reduces caspase-1 activity in the brain and anxiety like behavior.

Figure. 3

Figure. 3

Figure. 3

(A) Mice were administered ICV YVAD. 24 hours after YVAD administration caspase-1 activity was measured in the brain regions indicated. Results are expressed as means ± SEM nM/min/μg total protein; n=6-8 (*p<0.05). (B) Mice were treated as in (A). Total time spent in the open arms of the elevated zero maze was measured 24 hours after YVAD administration. Results are expressed as % time in the open arms of the maze; n=12–13 (*p<0.05). (C) Mice were treated as in (A). Total distance moved while in the elevated zero maze was measured 24 hours after YVAD administration. Results are expressed as distance moved in cm; n=12–13 (*p<0.05).